Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation

Bibliographic Details
Main Authors: Mariana Brandão, Fabien Reyal, Anne-Sophie Hamy, Martine Piccart-Gebhart
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/4/3/e000515.full
id doaj-95fa04b5acad47e3b0d17514a202a63f
record_format Article
spelling doaj-95fa04b5acad47e3b0d17514a202a63f2021-04-02T16:07:55ZengElsevierESMO Open2059-70292019-06-014310.1136/esmoopen-2019-000515Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligationMariana Brandão0Fabien Reyal1Anne-Sophie Hamy2Martine Piccart-Gebhart3Academic Trials Promoting Team, Institut Jules Bordet, Bruxelles, Belgium2 Residual Tumor & Response to Treatment Laboratory, PSL Research University, Paris, France 3 Breast and Gynecologic Cancer and Reconstructive Surgery Team, Institut Curie, Paris, France1 Université Libre de Bruxelles, Institut Jules Bordet, Bruxelles, Belgiumhttps://esmoopen.bmj.com/content/4/3/e000515.full
collection DOAJ
language English
format Article
sources DOAJ
author Mariana Brandão
Fabien Reyal
Anne-Sophie Hamy
Martine Piccart-Gebhart
spellingShingle Mariana Brandão
Fabien Reyal
Anne-Sophie Hamy
Martine Piccart-Gebhart
Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
ESMO Open
author_facet Mariana Brandão
Fabien Reyal
Anne-Sophie Hamy
Martine Piccart-Gebhart
author_sort Mariana Brandão
title Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_short Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_full Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_fullStr Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_full_unstemmed Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
title_sort neoadjuvant treatment for intermediate/high-risk her2-positive and triple-negative breast cancers: no longer an ‘option’ but an ethical obligation
publisher Elsevier
series ESMO Open
issn 2059-7029
publishDate 2019-06-01
url https://esmoopen.bmj.com/content/4/3/e000515.full
work_keys_str_mv AT marianabrandao neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT fabienreyal neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT annesophiehamy neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
AT martinepiccartgebhart neoadjuvanttreatmentforintermediatehighriskher2positiveandtriplenegativebreastcancersnolongeranoptionbutanethicalobligation
_version_ 1721557937647779840

Similar Items